Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Trial for Cryptococcal Meningitis
PACTR202502690170410Phase 2Not yet recruiting
- Sponsor
- David Boulware
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of oteseconazole and turletricin in cryptococcal meningitis (3 arms), sponsored by David Boulware. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
oteseconazoleturletricin
03
Conditions
cryptococcal meningitis
Beyond the preview
Go deeper on PACTR202502690170410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202502690170410.